Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways - Gilde Healthcare

Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways

February 20, 2017

LONDON AND NEW YORK – Today at HIMSS, Lumeon, a leading digital health company, and Digital Noema Telehealth (DN Telehealth), a provider of telemedicine and remote patient monitoring, announce they are partnering to optimize care pathways for telemedicine reimbursements.

DN Telehealth maximizes collaboration compatibility for its clients and their patients, in real-time, extending consultations beyond a physical clinical setting to include fully secure, web browser-based conferencing sessions.  The solution allows clinicians, caregivers and patients to extend care coordination to go beyond traditional care models, to optimize care and promote patient engagement of any “at risk” patient population, in a fully HIPAA-compliant environment.

Lumeon’s Care Pathway Manager seamlessly integrates clinical and administrative systems, and gives providers the ability to design and automate their own pathway rules, so that each patient is automatically progressed through their personal care journey based on their individual data.

“We’ve been looking for a care pathway automation partner for quite some time,” said Roque Espinal-Valdez, founder, and CEO of DN Telehealth. “With Lumeon’s functionality to automate and orchestrate the care pathway, previously manual tasks are eliminated and we can ensure that reimbursable elements are consistently used to deliver predictable outcomes for our customers in the managed care market.”

“Working with DN Telehealth provides us with the opportunity to address one of the fastest growing sectors within healthcare,” said Robbie Hughes, Lumeon CEO. “At the same time, our platform will enable customers of DN Telehealth to automate and orchestrate their care pathways to maximize reimbursement and improve efficiency of care delivery.”

The solution is available in North American and European markets from March 2017.

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term...
June 3, 2025

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
April 28, 2025